Arvinas is a clinical-stage biopharmaceutical company dedicated to improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development, and commercialization of therapies that degrade disease-causing proteins.






Org chart

John Houston
President & CEO

John Houston

John Northcott
Chief Commercial Officer
Ron Peck
Chief Medical Officer
Ian Taylor
Chief Scientific Officer
David Loomis
VP, Corporate Controller & Chief Accounting Officer
Lisa Sinclair
SVP, Corporate Operations
Paul McInulty
SVP, Regulatory Affairs
Kelly Page
SVP, Global Head of Oncology Strategy & Program Leadership
John A. Grosso
VP, Chemistry, Manufacturing, & Controls
Marcia Dougan Moore
VP, Development Operations
Randy Teel
VP, Corporate Development
Angela M. Cacace
VP, Neuroscience & Platform Biology
Kimberly Wehger
VP, Information Technology
Steve Weiss
VP, Human Resources
Jeff Boyle
VP, Investor Relations
Larry Snyder
VP, Medicinal Chemistry
Eric Masson
VP, Early Clinical Development
Christina Sheil
VP, Pharmacovigilance
Janice Kapty
VP, Estrogen Receptor Global Asset Lead
Brad Lanoue
VP, Global & U.S. Value & Market Access Strategy
Christopher Beck
VP, Intellectual Property
Charlie Romano
VP, Global Development Operations
Shelley Diaz
VP, Quality, Environmental Health & Safety
John Obourn
VP & Androgen Receptor Global Asset Lead
Janet Wang
VP & Head, Translational Sciences, Oncology